Why the study?
Specific therapies for pulmonary hypertension attributable to left heart disease have not been identified, and studies of pulmonary artery hypertension-targeted therapies show conflicting results.
This review highlights the lack of specific therapies for PH-LHD and explores emerging pathophysiological mechanisms like fibrosis, oxidative stress, and metabolic syndrome as potential novel therapeutic targets.
No takes yet. Share an insight, caveat, or question.
PH-LHD signals high mortality risk; confirms prognostic burden but leaves open targeted therapy development.
Lteif et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: